Connection
Christopher Porter to Neoplasms
This is a "connection" page, showing publications Christopher Porter has written about Neoplasms.
|
|
Connection Strength |
|
 |
|
 |
|
0.672 |
|
|
|
-
Mitchell SG, Pencheva B, Westfall E, Porter CC. Cancer Predisposition in Neonates and Infants: Recognition, Tumor Types, and Surveillance. Clin Perinatol. 2021 03; 48(1):1-14.
Score: 0.256
-
Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success? Lancet Oncol. 2013 Feb; 14(2):e70-8.
Score: 0.148
-
Alvarez SJA, Pencheva B, Westfall E, Mwalija C, Parsell M, Greenleaf M, Porter CC, Lam WA, Mannino RG, Mitchell SG. A novel mobile health application to support cancer surveillance needs of patients and families with cancer predisposition syndromes. Pediatr Blood Cancer. 2023 10; 70(10):e30537.
Score: 0.076
-
Birnbaum LA, Sullivan EC, Do P, Uricoli B, Raikar SS, Porter CC, Henry CJ, Dreaden EC. Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines. Biomacromolecules. 2023 03 13; 24(3):1164-1172.
Score: 0.074
-
Summers RJ, Castellino SM, Porter CC, MacDonald TJ, Basu GD, Szelinger S, Bhasin MK, Cash T, Carter AB, Castellino RC, Fangusaro JR, Mitchell SG, Pauly MG, Pencheva B, Wechsler DS, Graham DK, Goldsmith KC. Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. JCO Precis Oncol. 2022 04; 6:e2100451.
Score: 0.070
-
Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 04; 15(4):382-394.
Score: 0.049
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|